Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer

Total 87
Age 53 years (range: 28–83)
Menopausal status
 pre-menopausal 43 (50%)
 peri-menopausal 6 (7%)
 post-menopausal 38 (44%)
T stadium pre-NACT
 cT1a-cT1c 20 (23%)
 cT2 51 (59%)
 >cT2 14 (16%)
 Unknown 2 (2%)
T stadium post-NACT
 ypT0, ypTis 18 (21%)
 ypT1a 11 (13%)
 ypT1b, ypT1c 18 (21%)
 ypT2 26 (30%)
 >ypT2 10 (12%)
 Unknown 4 (5%)
N stadium pre-NACT
 cN0 41 (47%)
 cN1 40 (46%)
 cN2, cN3 5 (6%)
 Unknown 1 (1%)
N stadium post-NACT
 yN0 47 (54%)
 yN1 29 (33%)
 yN2/N3 8 (9%)
 Unknown 3 (4%)
Tumor type
 Ductal invasive 60 (69%)
 Lobular invasive 11 (13%)
 Other 14 (16%)
 Unknown 2 (2%)
Tumor grade
 G1 4 (5%)
 G2 40 (46%)
 G3 42 (48%)
 Unknown 1 (1%)
Estrogen receptor (IHC)a
 Positive 68 (78%)
 Negative 19 (22%)
Progesterone receptor (IHC)a
 Positive 58 (67%)
 Negative 29 (33%)
HER2 a
 Positive 23 (26%)
 Negative 64 (74%)
Tumor subtype
 ER-, PR-, HER2- 14 (16%)
 ER-, PR-, HER2+ 4 (5%)
 ER+/PR+, HER2- 50 (58%)
 ER+, PR+, HER2+ 19 (22%)
NACT regimen
 CTX 53 (61%)
 CTX + Trastuzumab 14 (16%)
 CTX + Avastin 4 (5%)
 CTX + Lapatinib + Trastuzumab 6 (7%)
 HTX 9 (10%)
 Unknown 1 (1%)
Trastuzumab treatment
 Yes 20 (23%)
 No 66 (76%)
 Unknown 1 (1%)
Clinical response
 pCR 15 (17%)
 pPR 62 (71%)
 pNC 6 (7%)
 Unknown 4 (5%)
Histological tumor regression gradeb
 0 6 (7%)
 1 32 (37%)
 2 22 (25%)
 3 5 (6%)
 4 12 (14%)
 Unknown 10 (12%)
Local treatment
 Mastectomy 56 (64%)
 Breast conservation surgery 26 (30%)
 Unknown 5 (6%)
DTC positive
 pre-NACT 16 (18%)
 post-NACT 13 (15%)
  1. aPositive ER and PR status (ER+, PR+) was defined based on the guidelines of the American Society of Clinical Oncology [88] and concordant German recommendations at that time. Accordingly, we used a cut off value of 1% for ER and PR status. Breast cancers were defined as HER2-positive (HER2+) only for those cases that were + 3 by immunohistochemistry (IHC) (cut off 30%) or + 2 on IHC and confirmed positive by CISH [89]. Respective results were not re-defined because they served as a basis for therapy decision at baseline
  2. b[48]